| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
ADAM-17: a novel therapeutic target for triple negative breast cancer
|
McGowan, P.M.
|
|
|
24 |
2 |
p. 362-369
|
article
|
| 2 |
Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial
|
Mesía, R.
|
|
|
24 |
2 |
p. 448-453
|
article
|
| 3 |
A meta-analysis of alcohol consumption and the risk of brain tumours
|
Galeone, C.
|
|
|
24 |
2 |
p. 514-523
|
article
|
| 4 |
A population-based cohort study in Taiwan––use of insulin sensitizers can decrease cancer risk in diabetic patients?
|
Kao, C.-H.
|
|
|
24 |
2 |
p. 523-530
|
article
|
| 5 |
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
|
Heidenreich, A.
|
|
|
24 |
2 |
p. 329-336
|
article
|
| 6 |
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
|
Steinmetz, T.
|
|
|
24 |
2 |
p. 475-482
|
article
|
| 7 |
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
|
Gibney, G.T.
|
|
|
24 |
2 |
p. 343-349
|
article
|
| 8 |
Cutaneous effects of BRAF inhibitor therapy: a case series
|
Mattei, P.L.
|
|
|
24 |
2 |
p. 530-537
|
article
|
| 9 |
Different outcome variables yield different results!
|
Brouckaert, O.
|
|
|
24 |
2 |
p. 554
|
article
|
| 10 |
Editorial Board
|
|
|
|
24 |
2 |
p. ii-iii
|
article
|
| 11 |
Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study
|
Yun, Y.H.
|
|
|
24 |
2 |
p. 489-494
|
article
|
| 12 |
Embryonic stem cell pathways and chemotherapy response: an unexplored route
|
Duhagon, M.A.
|
|
|
24 |
2 |
p. 558-559
|
article
|
| 13 |
Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?
|
Biganzoli, L.
|
|
|
24 |
2 |
p. 494-500
|
article
|
| 14 |
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
|
Nooka, A.K.
|
|
|
24 |
2 |
p. 441-448
|
article
|
| 15 |
Genomic grade adds prognostic value in invasive lobular carcinoma †
|
Metzger-Filho, O.
|
|
|
24 |
2 |
p. 377-384
|
article
|
| 16 |
Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans
|
Fedirko, V.
|
|
|
24 |
2 |
p. 543-553
|
article
|
| 17 |
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
|
Penel, N.
|
|
|
24 |
2 |
p. 537-542
|
article
|
| 18 |
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
|
Vaz-Luis, I.
|
|
|
24 |
2 |
p. 283-291
|
article
|
| 19 |
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
|
Goss, P.E.
|
|
|
24 |
2 |
p. 355-361
|
article
|
| 20 |
Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy
|
Bains, P.
|
|
|
24 |
2 |
p. 428-432
|
article
|
| 21 |
Light alcohol drinking and cancer: a meta-analysis
|
Bagnardi, V.
|
|
|
24 |
2 |
p. 301-308
|
article
|
| 22 |
Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study
|
Janus, N.
|
|
|
24 |
2 |
p. 501-507
|
article
|
| 23 |
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
|
André, T.
|
|
|
24 |
2 |
p. 412-419
|
article
|
| 24 |
Patient–doctor agreement on recall of clinical trial discussion across cultures
|
Bernhard, J.
|
|
|
24 |
2 |
p. 391-397
|
article
|
| 25 |
Pertuzumab: new hope for patients with HER2-positive breast cancer
|
Capelan, M.
|
|
|
24 |
2 |
p. 273-282
|
article
|
| 26 |
Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case–control studies
|
Kane, E.V.
|
|
|
24 |
2 |
p. 433-441
|
article
|
| 27 |
Prediction of axillary lymph node status in male breast carcinoma
|
Vaysse, C.
|
|
|
24 |
2 |
p. 370-376
|
article
|
| 28 |
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial
|
Vilmar, A.C.
|
|
|
24 |
2 |
p. 309-314
|
article
|
| 29 |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen, I.C.
|
|
|
24 |
2 |
p. 463-468
|
article
|
| 30 |
Prognosticating in patients with advanced cancer—observational study comparing the accuracy of clinicians’ and patients’ estimates of survival
|
Gwilliam, B.
|
|
|
24 |
2 |
p. 482-488
|
article
|
| 31 |
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data
|
Lintermans, A.
|
|
|
24 |
2 |
p. 350-355
|
article
|
| 32 |
Psychological effect of exercise in women with breast cancer receiving adjuvant therapy: what is the optimal dose needed?
|
Carayol, M.
|
|
|
24 |
2 |
p. 291-300
|
article
|
| 33 |
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
|
Aggarwal, C.
|
|
|
24 |
2 |
p. 420-428
|
article
|
| 34 |
Reply to ‘Different outcome variables yield different results’, by O. Brouckaert et al.
|
Truin, W.
|
|
|
24 |
2 |
p. 555
|
article
|
| 35 |
Reply to ‘Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease’ by U. Gueth et al
|
Aebi, S.
|
|
|
24 |
2 |
p. 557
|
article
|
| 36 |
Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study
|
Brunello, A.
|
|
|
24 |
2 |
p. 336-342
|
article
|
| 37 |
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
|
Socinski, M.A.
|
|
|
24 |
2 |
p. 314-321
|
article
|
| 38 |
Screening elderly cancer patients for disabilities: evaluation of study of osteoporotic fractures (SOF) index and comprehensive geriatric assessment (CGA)
|
Luciani, A.
|
|
|
24 |
2 |
p. 469-474
|
article
|
| 39 |
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
|
Pressiani, T.
|
|
|
24 |
2 |
p. 406-411
|
article
|
| 40 |
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: ‘plus or minus’ may be a minus
|
Dorff, T.B.
|
|
|
24 |
2 |
p. 270-272
|
article
|
| 41 |
Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease
|
Güth, U.
|
|
|
24 |
2 |
p. 555-557
|
article
|
| 42 |
Table of Contents
|
|
|
|
24 |
2 |
p. iv-vii
|
article
|
| 43 |
Testicular cancer in Europe and the USA: survival still rising among older patients
|
Verhoeven, R.H.A.
|
|
|
24 |
2 |
p. 508-513
|
article
|
| 44 |
Testis cancer: on gilding the lily
|
Raghavan, D.
|
|
|
24 |
2 |
p. 269-270
|
article
|
| 45 |
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
|
Cavaletti, G.
|
|
|
24 |
2 |
p. 454-462
|
article
|
| 46 |
The low opioid consumption in Italy depends on late palliative care
|
Mercadante, S.
|
|
|
24 |
2 |
p. 558
|
article
|
| 47 |
The prognostic role of TGF-β signaling pathway in breast cancer patients
|
de Kruijf, E.M.
|
|
|
24 |
2 |
p. 384-390
|
article
|
| 48 |
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors
|
Massard, C.
|
|
|
24 |
2 |
p. 322-328
|
article
|
| 49 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|
Coleman, R.
|
|
|
24 |
2 |
p. 398-405
|
article
|
Journal description